London, September 23, 2026 – Lift Therapeutics (‘Lift’ or ‘the Company’) today announced the appointment of Daniel Passeri, MSc, JD, as Chief Executive Officer (CEO). Mr. Passeri brings over 30 years of experience in oncology drug development, corporate strategy, and executive leadership, most recently serving as CEO of Cue Biopharma, where he led the company from inception into clinical development. Mr. Passeri succeeds Bo Rode Hansen, PhD, a member of Lift’s Board of Directors since 2023, who was appointed Interim CEO earlier this year during the search for a permanent CEO. Dr. Hansen will resume his role as a member of the Board of Directors and assume the role of President, where he will continue to leverage his deep corporate strategy and drug development experience to support the Company’s clinical development progress. LIfT Biosciences has been renamed Lift Therapeutics.